Cytomel and Breastfeeding
Studies on Cytomel (liothyronine) and breastfeeding suggest that small amounts of the medication pass through breast milk. These amounts are not expected to cause any problems, however, and they are also not high enough to treat hypothyroidism in an infant. Before using Cytomel, breastfeeding women should talk to their healthcare providers about the benefits and potential risks.
Cytomel® (liothyronine sodium) passes through breast milk in humans, although it typically does not cause any problems. If you are breastfeeding, you should talk with your healthcare provider before taking Cytomel.
Studies suggest that only small amounts of Cytomel pass through breast milk, just like natural thyroid hormones. This is not enough to treat an underactive thyroid in an infant. Instead, the infant must be treated directly.
If your thyroid hormone levels are kept at normal levels, there is no reason to expect that Cytomel would cause any problems during breastfeeding. In fact, women with an underactive thyroid (hypothyroidism) may not be capable of lactating properly unless they are treated, whether with Cytomel or other forms of thyroid replacement.
You should talk with your healthcare provider about Cytomel and breastfeeding. Each woman's situation is different, and you and your healthcare provider understand your situation best. After considering what you want and expect, as well as your current health situation, the two of you can make a shared decision about Cytomel and breastfeeding that is right for you. In general, the drug is considered safe for women who are breastfeeding and for their infants.